Literature DB >> 22236484

Group B Streptococcus infections in non-pregnant adults: the role of immunosuppression.

Bharath Sunkara1, Suchitha Bheemreddy, Bibi Lorber, Paul R Lephart, Kayoko Hayakawa, Jack D Sobel, Keith S Kaye, Dror Marchaim.   

Abstract

BACKGROUND: Group B Streptococcus (GBS) is a known causative pathogen of neonatal sepsis, but the epidemiology in non-pregnant adults is less studied.
METHODS: Retrospective case-control and cohort analyses of risk factors and outcomes of GBS infections among non-pregnant adults were conducted at the Detroit Medical Center from January 2005 to May 2010. Uninfected controls were matched to cases in a 3:1 ratio. Data were obtained from charts and pharmacy records. Identification of the bacteria and antimicrobial susceptibility testing were determined by MicroScan. Cox regression was used for matched multivariate analyses.
RESULTS: Thirty-two patients with GBS infections were identified and were matched and compared to 96 controls. Compared to controls, patients with GBS infection were significantly younger. Immunosuppression, attributable mainly to neutropenia and recent use of glucocorticoids, was an independent predictor for GBS infection (odds ratio 2.7, p=0.03). Nine (28%) of the patients with GBS infection had bacteriological failure despite the administration of appropriate antimicrobial therapy. Of the 10 patients with bloodstream infections (BSI), three had endocarditis and four had central nervous system (CNS) infections. During the study period the incidence of infections decreased, but the rates of resistance to erythromycin and clindamycin increased.
CONCLUSIONS: GBS, previously considered a genitourinary pathogen, has emerged as a non-nosocomial opportunistic pathogen causing BSI, endocarditis, and CNS infections. Immunosuppression, particularly transient immunosuppressed states, was an independent predictor for GBS BSI. Resistance rates to macrolides and clindamycin continue to increase, and should be closely monitored.
Copyright © 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236484     DOI: 10.1016/j.ijid.2011.11.008

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  18 in total

1.  Diminished Capsule Exacerbates Virulence, Blood-Brain Barrier Penetration, Intracellular Persistence, and Antibiotic Evasion of Hyperhemolytic Group B Streptococci.

Authors:  Claire Gendrin; Sean Merillat; Jay Vornhagen; Michelle Coleman; Blair Armistead; Lisa Ngo; Anjali Aggarwal; Phoenicia Quach; Jacob Berrigan; Lakshmi Rajagopal
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

2.  Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.

Authors:  Min Joo Choi; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Shun-Mei Lin; Yong Zhi; Jae Hyang Lim; Sangyong Lim; Ho Seong Seo; Joon Young Song
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

3.  Evaluation of Control Program Against Streptococcus agalactiae Infection in Dairy Herds During 2019-2021 in Emilia-Romagna Region, Northern Italy.

Authors:  Marco Tamba; Rossella Rocca; Alice Prosperi; Giovanni Pupillo; Patrizia Bassi; Giorgio Galletti; Enrica Martini; Annalisa Santi; Gabriele Casadei; Norma Arrigoni
Journal:  Front Vet Sci       Date:  2022-06-23

4.  Peripheral T-lymphocyte and natural killer cell population imbalance is associated with septic encephalopathy in patients with severe sepsis.

Authors:  Cheng-Xiang Lu; Ting Qiu; Hua-Sheng Tong; Zhi-Feng Liu; Lei Su; Biao Cheng
Journal:  Exp Ther Med       Date:  2016-01-15       Impact factor: 2.447

5.  Streptococcus agalactiae endocarditis presenting as acalculous cholecystitis in a previously well woman.

Authors:  Linda Brewer; Amanda Hanora Lavan; Laura Cullen; Joseph Duggan
Journal:  BMJ Case Rep       Date:  2013-02-11

6.  Endocytosis‒Mediated Invasion and Pathogenicity of Streptococcus agalactiae in Rat Cardiomyocyte (H9C2).

Authors:  Sharma Pooja; Muthuirulan Pushpanathan; Paramasamy Gunasekaran; Jeyaprakash Rajendhran
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

7.  Evidence of Common Isolates of Streptococcus agalactiae in Bovines and Humans in Emilia Romagna Region (Northern Italy).

Authors:  Elena Carra; Simone Russo; Alessia Micheli; Chiara Garbarino; Matteo Ricchi; Federica Bergamini; Patrizia Bassi; Alice Prosperi; Silvia Piva; Monica Cricca; Roberta Schiavo; Giuseppe Merialdi; Andrea Serraino; Norma Arrigoni
Journal:  Front Microbiol       Date:  2021-06-11       Impact factor: 5.640

8.  Role of the serine-rich surface glycoprotein Srr1 of Streptococcus agalactiae in the pathogenesis of infective endocarditis.

Authors:  Ho Seong Seo; Yan Q Xiong; Paul M Sullam
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

9.  Group B streptococcus infections of soft tissue and bone in California adults, 1995-2012.

Authors:  E M Smith; M A Khan; A Reingold; J P Watt
Journal:  Epidemiol Infect       Date:  2015-11       Impact factor: 4.434

10.  Characterization of fibrinogen binding by glycoproteins Srr1 and Srr2 of Streptococcus agalactiae.

Authors:  Ho Seong Seo; George Minasov; Ravin Seepersaud; Kelly S Doran; Ievgeniia Dubrovska; Ludmilla Shuvalova; Wayne F Anderson; Tina M Iverson; Paul M Sullam
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.